The global Immunology Market size, valued at USD 97.58 billion in 2023, is projected to witness exponential growth to USD 254.23 billion by 2032, expanding at a Compound Annual Growth Rate (CAGR) of 11.8%. This surge is primarily attributed to the increasing prevalence of autoimmune diseases, rising demand for biologics and precision medicine, and continuous advancement in regulatory drug approvals worldwide.
Rising Autoimmune Disorders Continue to Drive Immunology Market Expansion
Autoimmune diseases are steadily increasing due to several environmental and lifestyle factors such as exposure to toxic chemicals, chronic stress, dietary imbalances, gut dysbiosis, and infections. These conditions have rendered autoimmune diseases the third most prevalent chronic illness in the United States, affecting nearly 50 million Americans.
A significant 2023 study by the University of Oxford, which examined 22 million individuals in the UK, revealed that 1 in 10 people suffers from some form of autoimmune disorder. As awareness continues to grow and diagnostic capabilities improve, the demand for effective immunological therapies is set to skyrocket.
Get a Sample Report of Immunology Market@ https://www.snsinsider.com/sample-request/4188
Immunology Market Growth Driven by Biologic Therapies and Targeted Drug Approvals
The development and commercialization of biologics and targeted immunotherapies have revolutionized the immunology landscape. Recent regulatory approvals underscore the ongoing innovation:
- February 2023 – Regeneron Pharmaceuticals, Inc. and Sanofi gained FDA approval for KEVZARA for treating polymyalgia rheumatica.
- March 2023 – Eli Lilly launched Copellor for psoriasis and psoriatic arthritis treatment in India.
- June 2023 – Sandoz released Hyrimoz, a high-concentration injectable for multiple inflammatory conditions.
Such advancements are expected to further accelerate global adoption of advanced immunological treatments.
Market Dynamics – Drivers, Challenges, and Opportunities
Key Drivers
- Rising cases of rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes globally.
- Accelerated research and development in biologics, biosimilars, and immunotherapies.
- Significant public and private investment in healthcare infrastructure and innovation.
Restraints
- High cost of biologics and limited insurance coverage in developing countries.
- Stringent regulatory hurdles impacting drug approval timelines and clinical trial success rates.
Opportunities
- The emergence of immunotherapy in oncology is unlocking new potential beyond autoimmune diseases.
- Precision medicine and personalized treatments are attracting investor attention and transforming patient care.
Immunology Market Segmentation Analysis
By Drug Class
The monoclonal antibody (mAb) segment held a commanding 58% market share in 2023, owing to their efficacy in treating rare and chronic autoimmune diseases. Key examples include rituximab, infliximab, and adalimumab.
In January 2023, Gilead Sciences partnered with EVOQ Therapeutics to develop treatments for rheumatoid arthritis and lupus using NanoDisc technology, further fueling segment expansion.
Meanwhile, the immunosuppressants segment is anticipated to record the highest CAGR over the forecast period, driven by:
- Enhanced R&D pipelines and successful clinical trials.
- Widespread usage in emerging markets due to rising affordability.
By Indication
The rheumatoid arthritis segment dominated in 2023 with a 43% share. According to 2023 data from the Australian Bureau of Statistics, 13.9% of Australians diagnosed with arthritis suffer from rheumatoid arthritis, highlighting a high demand for treatment options.
In contrast, limited drug options for conditions like ankylosing spondylitis and inflammatory bowel disease have tempered growth in those sub-segments, especially in lower-income markets.
Need Any Customization Research on Immunology Market, Enquire Now@ https://www.snsinsider.com/enquiry/4188
Regional Insights – North America Leads, Asia-Pacific Emerging Rapidly
North America
The region captured a 32% market share in 2023, propelled by:
- Strong healthcare infrastructure
- High prevalence of autoimmune conditions
- Swift adoption of cutting-edge therapeutics
The U.S. has also been a leader in advancing women’s health in relation to autoimmune conditions. In February 2022, the NIH webinar on autoimmune diseases highlighted that 80% of autoimmune patients are women, intensifying focus on gender-specific treatment protocols.
Europe
Europe continues its legacy in biotechnological innovation, with countries like Germany, France, and the UK leading the development of novel immunotherapies and clinical trial frameworks.
Asia-Pacific
This region is forecasted to experience the fastest growth due to:
- Expanding healthcare budgets in countries like India, China, and Australia
- Increasing public-private partnerships
- Emphasis on affordable RNA-based therapies
For instance, in 2022, the Victorian Government in Australia funded a $100,000 research grant to the Hudson Institute of Medical Research to explore RNA therapeutics for autoimmune treatment.
Key Market Players in the Global Immunology Sector
Leading companies actively shaping the immunology market include:
- Novartis AG
- AbbVie Inc.
- Pfizer Inc.
- Amgen Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Astellas Pharma Inc.
- Janssen Global Services, LLC
These companies are focused on biologic innovation, regulatory navigation, and strategic acquisitions to strengthen their market footprint.
Recent Developments Highlight Market Momentum
- June 2023 – Sandoz launched Hyrimoz, expanding treatment access for RA and psoriatic arthritis.
- March 2023 – Eli Lilly received Indian approval for Copellor, addressing moderate-to-severe plaque psoriasis.
- June 2022 – FDA approved OLUMIANT by Eli Lilly for severe alopecia areata, marking a breakthrough for auto-immune related hair loss.
Outlook and Future Trends in the Immunology Market
Looking ahead, the immunology sector is expected to benefit from:
- Breakthroughs in genomics and proteomics
- Expanded focus on mRNA and RNA interference (RNAi) technologies
- Integration of digital health for monitoring treatment responses and drug efficacy
Furthermore, global initiatives such as the WHO’s Rehabilitation 2030 and the UN Decade of Healthy Ageing will play pivotal roles in expanding equitable access to immunological care and healthy ageing practices for chronic autoimmune patients.
Buy a Single-User PDF of Immunology Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4188
Table of Contents – Major Key Points
- Introduction
- Executive Summary
- Research Methodology
- Market Dynamics Impact Analysis
- Statistical Insights and Trends Reporting
- Competitive Landscape
- Immunology Market Segmentation, by Drug Class
- Immunology Market Segmentation, by Indication
- Immunology Market Segmentation, by Distribution Channel
- Regional Analysis
- Company Profiles
- Use Cases and Best Practices
- Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
